Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Reexamination Certificate
2007-03-27
2007-03-27
Achutamurthy, P. (Department: 1652)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
C435S252300, C435S320100, C435S004000, C435S006120, C435S069100, C435S325000, C435S254300, C424S094630, C536S023200, C536S023500, C514S789000
Reexamination Certificate
active
10441667
ABSTRACT:
A fibrinolytically active metalloproteinase polypeptide (called “novel acting thrombolytic”) which is useful for blood clot lysis in vivo and methods and materials for its production by recombinant expression are described.
REFERENCES:
patent: 4083961 (1978-04-01), Dussourdd'Hinterland et al.
patent: 4447236 (1984-05-01), Quinn
patent: 4610879 (1986-09-01), Markland et al.
patent: 4692139 (1987-09-01), Stiles
patent: 4755167 (1988-07-01), Thistle et al.
patent: 4812405 (1989-03-01), Lair et al.
patent: 4818700 (1989-04-01), Cregg et al.
patent: 4837148 (1989-06-01), Cregg
patent: 4855231 (1989-08-01), Stroman et al.
patent: 4885242 (1989-12-01), Cregg
patent: 5167628 (1992-12-01), Boyles
patent: 5222941 (1993-06-01), Don Michael
patent: 5250034 (1993-10-01), Appling et al.
patent: 5370653 (1994-12-01), Cragg
patent: 5380273 (1995-01-01), Dubrul et al.
patent: 5498236 (1996-03-01), Dubrul et al.
patent: 5626564 (1997-05-01), Zhan et al.
patent: 5709676 (1998-01-01), Alt
patent: 5830468 (1998-11-01), Bini
patent: 5865178 (1999-02-01), Yock
patent: 5922322 (1999-07-01), Bini
patent: 5951981 (1999-09-01), Markland, Jr. et al.
patent: 6020181 (2000-02-01), Bini
patent: 6107280 (2000-08-01), White et al.
patent: 6455269 (2002-09-01), Toombs
patent: 6759431 (2004-07-01), Hunter et al.
patent: 2002/0081685 (2002-06-01), Fox et al.
patent: 0 323 722 (1989-07-01), None
patent: 0 438 200 (1991-07-01), None
patent: 0 624 642 (1994-11-01), None
patent: 0 689 843 (1996-01-01), None
patent: WO90/07352 (1990-07-01), None
patent: WO 96/36227 (1996-11-01), None
patent: WO 98/24917 (1998-06-01), None
patent: WO 98/46771 (1998-10-01), None
patent: WO 01/24817 (2001-04-01), None
patent: WO 01/25445 (2001-04-01), None
patent: WO 02/12283 (2002-02-01), None
Guan et al., “Purification and characterization of a fibmiloytic enzyme from venom of the southern copperhead snakeAgkistrodon Contortrix Contortrix,” Archives of Biochemistry and Biophysics, 289 (2): 197-207 (1991).
Randolph et al., “Amino acid dequence of fibrolase, a driect-acting fibrinolytic enzyme fromAgkistrodon Contortrix Contortrixvenom,”Protein Science, vol. 1: 590-600 (1992).
Markland et al., “Thrombolytic effects of recombinant fibrolase or APSAC in a canine model of carotid artery thrombosis,”Circulationvol. 90 (5):2448-2456 (1994).
Loayza et al., “Resolution of isoforms of natural and recombinant fibrolase, the fibrinolytic enzyme fromAgkistrodon Contortrix Contortrixsnake venom, and comparison of their EDTA sensitivities,”Journal of Chromatography B 662:227-243 (1994).
Rholam et al., “Role of amino acid sequences flanking dibasic cleavage sites in precursor proteolytic processing-the importance of the first residue C-terminal of the cleavage site,”European Journal of Biochemistry 227:707-714 (1995).
Sreekrishna et al.,“Strategies for optimal synthusis and secretion of heterologous proteins in the methylotrophic yeastPichia pastoris,” Gene 190:55-62 (1997).
Ahmed et al., “Biochemical Characteristics of Fibrolase, a Fibrinolytic Protease from Snake Venom,”Haemostasis 20:147-154 (1990).
Ahmed et al., “Biological and Thrombolytic Properties of Fibrolase-A New Fibrinolytic Protease from Snake Venom,”Haemostasis 20:334-340 (1990).
Manning, M. “Sequence Analysis of Fibrolase, A Fibrinolytic Metalloproteinase fromAgkistrodon Contortrix Contortrix,” Toxicon 33(9): 189-1200 (1995).
Markland et al., “Resolution of Isoforms of Natural and Recombinant Fibrinolytic Snake Venom Enzyme Using High Performance Capillary Electrophoresis,”Journal of Liquid Chromatography 16(9-10):2189-2201 (1993).
Potempa et al., “Stabilization vs. degradation ofStaphylococcus aureusmetalloproteinase,”Biochimica et Biophysica Acia, 993:301-304 (1989).
Williams et al., “The lyophilization of pharmaceuticals: a literature review,”J. Parenter Sci Technol 38:48-59 (1984).
Chen, “Formulation Concerns of Protein Drugs,”Drug Development and Industrial Pharmacy, 18(11-12):1311-1354 (1992).
Carpenter et al., “Interactions of Stabilizing Additives with Proteins During Freeze-Thawing and Freeze-Drying,”Developments in Biological Standardization 74:225-239 (1991).
[No authors listed], “Results of a Prospective Randomized Trial Evaluating Surgery Versus Thrombolysis for Ischemia of the Lower Extremity,” The Stile Trial, Stile Investigators Appendix A,Annals of Surgery, 220(3):251-266 (1994).
Barrett, A.J. (ed.),Methods in Enzymology, Academic Press, Inc., Philadelphia, PA, pp. 737-754 (1981).
Jackson and Claggett, “Antithrombotic Therapy in Peripheral Arterial Occlusive Disease,”Chest, 114:666S-682S (1998).
Ouriell et al., “A Comparision of thrombolyutic therapy with operative revascularization in the initial treatment of acute perpheral arterial ischemia,”Journal of Vascular Surgery, 19:1021-1030 (1994).
Ouriellet al., “A Comparison of recombinant Urokinase with Vascular Surgery as Initial Treatment for Acute Arterial Occlusion of the Legs,”New England Journal of Medicine, 338:1105-1111 (1998).
Pretzer et al., “Stability of the Thrombolytic Protein Fibrolase: Effect of temperature and pH on Activity and Conformation,”Pharmaceutical Research, 8(9):1103-1112 (1991).
Pretzer et al., “Effect of Zinc Binding on the Structure and Stability of Fibriolase, a Fibrinloytic Protein from Snake Venom,”Pharmaceutical Research, 9(7):870-877 (1992).
Retzios et al., “Fibrinolytic Enzymes from the Venoms ofAgkistrodon contortrix contortricxandCrotalus basiliscus baslliscus,” Thrombosis Research, 74(4):355-367 (1994).
Kandarpa et al., “Forceful Pulsatile Local Infusion of Enzyme Accelerates Thrombolysis: In Vivo Evaluation of a New Delivery System,”Radiology, 168:739-744 (1981).
Anai et al., “Inhibition of a Snake Venom Hemorrhagic Metalloproteinase by Human and Rat Alpha-Macroglobulins,” Toxicon: Official Journal of the International Society on Toxinology, 36(8):1127-1139 (1998).
Bode et al., Astacins, Serralysins, Snake Venom and Matrix Metalloproteinases Exhibit Indentical Zinc-Binding Environments (HEXXHXXGXXH And Met-Turn) and Topologies and Should be Grouped into a Common Family, the ‘Metzinchins’, FEBS Lett, 331(1-2):134-140 (1993).
de Araujo et al., “Molecular Cloning and Sequence Analysis of CDNAS for Metalloproteinases From Broad-Banded CopperheadAgkistrodon contortrix laticinctus”, Archives of Biochemistry and Biophysics 320(1):141-148 (1995).
Stocker et al., “The Metzincins-Topological and Sequential Relations Between the Astacins, Adamalysins, Serralysins, and Matrixins (Collagenases Define a Superfamily of Zinc-Peptidases,” Protein Sci., 4(5):823-840 (1995).
Verstraete et al., “Thrombolytic Agents in Development,” Drugs, 50(1):29-42 (1995).
Boone Thomas C.
Li Huimin
Mann Michael B.
Achutamurthy P.
Amgen Inc.
Pak Yong D.
Robins & Pasternak LLP
LandOfFree
Methods for the treatment of thrombosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment of thrombosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of thrombosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3766326